摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(E)-1-(1H-benzoimidazol-5-yl)-5-(3,5-dibromo-phenyl)-4-(3-phenyl-propylimino)-imidazolidine-2-thione | 1025453-91-1

中文名称
——
中文别名
——
英文名称
(E)-1-(1H-benzoimidazol-5-yl)-5-(3,5-dibromo-phenyl)-4-(3-phenyl-propylimino)-imidazolidine-2-thione
英文别名
1-(3H-benzimidazol-5-yl)-5-(3,5-dibromophenyl)-4-(3-phenylpropylimino)imidazolidine-2-thione
(E)-1-(1H-benzoimidazol-5-yl)-5-(3,5-dibromo-phenyl)-4-(3-phenyl-propylimino)-imidazolidine-2-thione化学式
CAS
1025453-91-1
化学式
C25H21Br2N5S
mdl
——
分子量
583.349
InChiKey
ZZTVPHBKVVIGHH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.3
  • 重原子数:
    33
  • 可旋转键数:
    7
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.16
  • 拓扑面积:
    88.4
  • 氢给体数:
    2
  • 氢受体数:
    2

文献信息

  • Novel Inhibitors of Glutaminyl Cyclase
    申请人:Thormann Michael
    公开号:US20080221086A1
    公开(公告)日:2008-09-11
    The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein R 1 represents heteroaryl; -carbocyclyl-heteroaryl; -alkenylheteroaryl or -alkylheteroaryl; R 2 represents alkyl which may optionally be substituted by hydroxy; carbocyclyl, which may optionally be substituted by one or more groups selected from alkyl and hydroxy; aryl; -aryl-heteroaryl; -heteroaryl-aryl; -aryl-heterocyclyl; H; heteroaryl; or heterocyclyl, which may optionally be substituted by one or more groups selected from alkyl oxo and hydroxy; R 3 represents alkyl which may optionally be substituted by one of more groups selected from alkoxy, amine, hydroxy and —C(O)Oalkyl; carbocyclyl, which may optionally be substituted by one or more groups selected from alkyl haloalkyl, alkoxy, amine, hydroxy and —C(O)Oalkyl; -alkyl-aryl; -alkyl(aryl) 2 ; -alkyl-heteroaryl; -alkyl(heteroaryl) 2 ; -alkyl(heteroaryl)(aryl); -aryl-O-aryl; aryl; heterocyclyl, -alkyl-C(O)-heterocyclyl, -alkyl-heterocyclyl, -alkyl-C(O)—NR 5 -heterocyclyl or -alkyl(heterocyclyl) 2 in any of which groups heterocyclyl may be optionally substituted by one or more groups selected from alkyl hydroxy and oxo; -heteroaryl; or -hydroxyalkylaryl; R 4 represents H or C 1-3 alkyl; R 5 represents H or C 1-3 alkyl; and X represents O or S.
    本发明涉及式(I)的化合物,其组合物和用于疾病治疗的用途,或其药学上可接受的盐,溶剂或多晶形式,包括其所有互变异构体和立体异构体,其中R1表示杂环芳基;-碳环芳基-杂环芳基;-烯基杂环芳基或-烷基杂环芳基;R2表示烷基,其可以选择性地被羟基取代;碳环芳基,其可以选择性地被一种或多种从烷基和羟基中选择的基团取代;芳基;-芳基-杂环芳基;-杂环芳基-芳基;-芳基-杂环环基;H;杂环芳基;或杂环环基,其可以选择性地被一种或多种从烷基氧化物和羟基中选择的基团取代;R3表示烷基,其可以选择性地被一种或多种从烷氧基,胺基,羟基和-C(O)O烷基中选择的基团取代;碳环芳基,其可以选择性地被一种或多种从烷基卤代烷基,烷氧基,胺基,羟基和-C(O)O烷基中选择的基团取代;-烷基-芳基;-烷基(芳基)2;-烷基-杂环芳基;-烷基(杂环芳基)2;-烷基(杂环芳基)(芳基);-芳基-O-芳基;芳基;杂环环基,-烷基-C(O)-杂环环基,-烷基-杂环环基,-烷基-C(O)-NR5-杂环环基或-烷基(杂环环基)2,在其中杂环环基可以选择性地被一种或多种从烷基,羟基和氧化物中选择的基团取代;-杂环芳基;或-羟基烷基芳基;R4表示H或C1-3烷基;R5表示H或C1-3烷基;且X表示O或S。
  • CHEMOKINE RECEPTOR BINDING COMPOUNDS
    申请人:ANORMED INC.
    公开号:EP1896023A2
    公开(公告)日:2008-03-12
  • NOVEL INHIBITORS OF GLUTAMINYL CYCLASE
    申请人:Probiodrug AG
    公开号:EP2091945B1
    公开(公告)日:2014-01-15
  • US8420684B2
    申请人:——
    公开号:US8420684B2
    公开(公告)日:2013-04-16
  • [EN] CHEMOKINE RECEPTOR BINDING COMPOUNDS<br/>[FR] COMPOSES DE LIAISON AUX RECEPTEURS DES CHIMIOKINES
    申请人:ANORMED INC
    公开号:WO2006138259A2
    公开(公告)日:2006-12-28
    [EN] The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
    [FR] L'invention concerne des composés de liaison aux récepteurs des chimiokines, des compositions pharmaceutiques et l'utilisation de ceux-ci. Plus précisément, l'invention concerne des modulateurs de l'activité des récepteurs des chimiokines, de préférence, des modulateurs de CCR5. Ces composés possèdent des effets protecteurs contre une infection des cellules cibles par le virus de l'immunodéficience humaine (VIH).
查看更多